TB-500: what the research says. | Reddit

TB-500 is a synthetic peptide sold and studied under a name that does not map cleanly onto a single molecule. In most commercial and research usage it refers to the 43-amino-acid thymosin beta-4 (Tβ4) protein, first isolated in 1981 by Allan Goldstein and colleagues at George Washington University. Other sources use the name for a shorter fragment containing the LKKTETQ active-site sequence.

That ambiguity is the single most important thing to understand before reading anything else about it. Two articles describing “TB-500” may be describing different compounds, and a study cited as evidence for one is often evidence for the other.

Not reliably. Thymosin beta-4 is a specific, well-characterised human protein with a defined sequence. TB-500 is a product name. When a vendor or forum post treats the two as interchangeable, they are making an assumption about what is in the vial rather than stating a verified fact.

This matters when reading research. The 1991 work by Safer and colleagues in the Journal of Biological Chemistry, which established Tβ4 as the primary actin-sequestering protein in mammalian cells, studied thymosin beta-4. It did not study a commercial product called TB-500.

Unlike peptides that bind a single receptor, thymosin beta-4 acts on actin, the structural protein that lets cells change shape and move. That is why the research spans tissues as different as muscle, cornea and heart: the proposed mechanism is general to cell movement rather than specific to one organ.

Thymosin beta-4 has a genuine, well-characterised biological role, and it has been further in human research than most peptides sold online. It has cleared Phase II randomised trials, but for topical and ophthalmic indications rather than for anything resembling how TB-500 is actually used.

A 2015 randomised, double-masked, placebo-controlled Phase II trial gave 0.1% thymosin beta-4 ophthalmic solution to 72 subjects with moderate to severe dry eye over 28 days (Clinical Ophthalmology). A double-blind, placebo-controlled dose-escalation study across ten sites in Italy and Poland tested topical thymosin beta-4 in venous ulcers (Ann NY Acad Sci, 2007). Both are real controlled human evidence. Neither involves injection, and neither addresses muscle, tendon or joint recovery.

No human pharmacokinetic profile has been established for TB-500 as sold. Figures circulated online, commonly in the range of two to three days, are not traceable to published human PK data, and half-life for a peptide varies with sequence, formulation and route.

The practical consequence is that dosing intervals presented online as settled are extrapolations. There is no validated schedule to extrapolate from.

There is no approved dose, because there is no approved indication. Dosing schedules published on forums and vendor sites are not derived from human trial data. They are described here as a description of what circulates, not as guidance, and nothing in this section should be read as a protocol.

There is no controlled human safety data for TB-500. That is a statement about the absence of evidence rather than a claim of safety, and it is the most important thing on this page from a risk perspective. Unknown is not the same as safe.

The precise answer is more specific than “legal” or “illegal.” TB-500 is not an FDA-approved drug. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a compounded medication only qualifies for its regulatory exemptions if the bulk substance has a USP monograph, is a component of an approved drug, or appears on the FDA’s 503A bulk substances list. Thymosin beta-4 is none of those.

The practical effect is that compounding it falls outside those exemptions, which makes the resulting product an unapproved new drug and exposes the pharmacy to FDA enforcement. That is an enforcement posture rather than a criminal prohibition, and it is the reason no established pharmacy network supplies it. The classification remains under FDA review and can change.

Products sold online are typically labelled “for research use only, not for human consumption.” That label is what allows them to be sold at all, and it is also an explicit statement that the seller is not offering a medicine.

Not through any legitimate clinical channel in the United States. It is sold online by research-chemical vendors, and buying it means accepting that no pharmacy, prescriber or regulator has verified what is in the vial.

Anything a licensed US pharmacy dispenses has to clear that regulatory bar first. Every dose PepScribe dispenses is compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain.

The two are frequently paired in recovery discussions and are often sold together. They share a regulatory position and an evidence problem, while differing in proposed mechanism.

Yes. Thymosin beta-4 appears on the World Anti-Doping Agency prohibited list and is banned at all times, in and out of competition. Athletes subject to anti-doping rules should treat any product marketed as TB-500 as prohibited, including where the label is ambiguous about its contents.

If the underlying goal is recovery, tissue maintenance or resilience as you age, there are therapies a licensed physician can actually prescribe and a licensed US pharmacy can actually prepare. That is a materially different proposition from a research chemical of unverified contents.